These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 24296828)
1. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Beauchamp EM; Woods BA; Dulak AM; Tan L; Xu C; Gray NS; Bass AJ; Wong KK; Meyerson M; Hammerman PS Mol Cancer Ther; 2014 Feb; 13(2):475-82. PubMed ID: 24296828 [TBL] [Abstract][Full Text] [Related]
2. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973 [TBL] [Abstract][Full Text] [Related]
3. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954 [TBL] [Abstract][Full Text] [Related]
4. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Pitini V; Arrigo C; Di Mirto C; Mondello P; Altavilla G Lung Cancer; 2013 Oct; 82(1):171-2. PubMed ID: 23932362 [TBL] [Abstract][Full Text] [Related]
5. NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333 [TBL] [Abstract][Full Text] [Related]
6. Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer. Nicoś M; Powrózek T; Krawczyk P; Jarosz B; Pająk B; Sawicki M; Kucharczyk K; Trojanowski T; Milanowski J Med Oncol; 2014 Oct; 31(10):176. PubMed ID: 25173530 [TBL] [Abstract][Full Text] [Related]
7. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. Terai H; Tan L; Beauchamp EM; Hatcher JM; Liu Q; Meyerson M; Gray NS; Hammerman PS ACS Chem Biol; 2015 Dec; 10(12):2687-96. PubMed ID: 26390252 [TBL] [Abstract][Full Text] [Related]
8. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Day E; Waters B; Spiegel K; Alnadaf T; Manley PW; Buchdunger E; Walker C; Jarai G Eur J Pharmacol; 2008 Dec; 599(1-3):44-53. PubMed ID: 18938156 [TBL] [Abstract][Full Text] [Related]
10. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Iwai LK; Payne LS; Luczynski MT; Chang F; Xu H; Clinton RW; Paul A; Esposito EA; Gridley S; Leitinger B; Naegle KM; Huang PH Biochem J; 2013 Sep; 454(3):501-13. PubMed ID: 23822953 [TBL] [Abstract][Full Text] [Related]
12. DDR2 inhibition reduces migration and invasion of murine metastatic melanoma cells by suppressing MMP2/9 expression through ERK/NF-κB pathway. Poudel B; Lee YM; Kim DK Acta Biochim Biophys Sin (Shanghai); 2015 Apr; 47(4):292-8. PubMed ID: 25733533 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. Miao L; Wang Y; Zhu S; Shi M; Li Y; Ding J; Yang J; Ye Q; Cai H; Zhang D; Liu H; Song Y BMC Cancer; 2014 May; 14():369. PubMed ID: 24885564 [TBL] [Abstract][Full Text] [Related]
14. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049 [TBL] [Abstract][Full Text] [Related]
15. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Ford CE; Lau SK; Zhu CQ; Andersson T; Tsao MS; Vogel WF Br J Cancer; 2007 Mar; 96(5):808-14. PubMed ID: 17299390 [TBL] [Abstract][Full Text] [Related]
16. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sen B; Peng S; Tang X; Erickson HS; Galindo H; Mazumdar T; Stewart DJ; Wistuba I; Johnson FM Sci Transl Med; 2012 May; 4(136):136ra70. PubMed ID: 22649091 [TBL] [Abstract][Full Text] [Related]
17. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein. Yan Z; Jin S; Wei Z; Huilian H; Zhanhai Y; Yue T; Juan L; Jing L; Libo Y; Xu L Biochim Biophys Acta; 2014 Sep; 1842(9):1350-63. PubMed ID: 24787381 [TBL] [Abstract][Full Text] [Related]
18. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Dumka D; Puri P; Carayol N; Lumby C; Balachandran H; Schuster K; Verma AK; Terada LS; Platanias LC; Parmar S Leuk Lymphoma; 2009 Dec; 50(12):2017-29. PubMed ID: 19672773 [TBL] [Abstract][Full Text] [Related]
19. Discoidin domain receptor 2 mediates the collagen II-dependent release of interleukin-6 in primary human chondrocytes. Klatt AR; Zech D; Kühn G; Paul-Klausch B; Klinger G; Renno JH; Schmidt J; Malchau G; Wielckens K J Pathol; 2009 Jun; 218(2):241-7. PubMed ID: 19267386 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma. Xu J; Lu W; Zhang S; Zhu C; Ren T; Zhu T; Zhao H; Liu Y; Su J Cancer Biol Ther; 2014 May; 15(5):612-22. PubMed ID: 24556606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]